Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Waldenstrom Macroglobulinemia 1Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1Leukemia, Lymphocytic, Chronic, B-Cell 1

Interventions

Rituximab 19Cyclophosphamide 12Peripheral Blood Stem Cell Transplantation 10Filgrastim 10fludarabine phosphate 9Bortezomib 9Radiotherapy 8Cyclosporine 8tanespimycin 6Prednisone 6Magnetic Resonance Spectroscopy 6Etoposide 6Vorinostat 5Vincristine 5Lenalidomide 5Indium 5Ifosfamide 5temsirolimus 4bryostatin 1 4alvocidib 4Paclitaxel 4Interferon-alpha 4Gemcitabine 4Doxorubicin 4Cytarabine 4Busulfan 4sargramostim 3ibrutinib 3apolizumab 3aldesleukin 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Lymphoma, B-Cell, Marginal Zone × oprelvekin × Clear all
NCT00012298 2018-08-09

Radiolabeled Monoclonal Antibody Plus Rituximab With and Without Filgrastim and Interleukin-11 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

National Cancer Institute (NCI)

Phase 1/2 Terminated
81 enrolled 16 charts
LymphoidOther hematologic neoplasm

Lymphoma, Follicular, Waldenstrom Macroglobulinemia, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Marginal Zone

Data powered by HemOnc (CC BY 4.0) Colophon âš¡